Athersys Inc
OTC:ATHXQ

Watchlist Manager
Athersys Inc Logo
Athersys Inc
OTC:ATHXQ
Watchlist
Price: 0.0001 USD
Market Cap: 61.7 USD

Athersys Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Athersys Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Athersys Inc
OTC:ATHXQ
Net Income (Common)
-$37.5m
CAGR 3-Years
17%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Athersys Inc
Glance View

Market Cap
61.7 USD
Industry
Biotechnology

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. The company is headquartered in Cleveland, Ohio and currently employs 104 full-time employees. The company went IPO on 2007-04-23. The company is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The company is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.

ATHXQ Intrinsic Value
Not Available

See Also

What is Athersys Inc's Net Income (Common)?
Net Income (Common)
-37.5m USD

Based on the financial report for Sep 30, 2023, Athersys Inc's Net Income (Common) amounts to -37.5m USD.

What is Athersys Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-4%

Over the last year, the Net Income (Common) growth was 54%. The average annual Net Income (Common) growth rates for Athersys Inc have been 17% over the past three years , -8% over the past five years , and -4% over the past ten years .

Back to Top